Menu

CareDx, Inc. CDNA

Full chart Compare
Set alert

Price alert · CDNA

All alert types
77.97 USD +1.64 (+2.15%)

Nov 6, 2026, 3:27 PM EST

75.93 Day range 80.55
14.72 52-week range 90.87
YTD
+313.85%
1 year
+419.45%
Market cap
4.10B
Revenue (ttm)
497.40M
Profit margin
25.86%
EPS (ttm)
2.37
Shares out
52.54M
P/E ratio
32.90
Forward P/E
48.36
YTD return
+313.85%
1-year return
+419.45%
Volume
798.79K
Avg volume
1.32M
Open
77.88
Previous close
76.33
Day's range
75.93 – 80.55
52-week range
14.72 – 90.87
Beta
2.49
Analysts
Buy
Price target
93.50 (+19.9%)
Earnings date
Feb 23, 2027

5D -9.68 (-11.05%)

808590MonTueWedThuFri77.92

Key statistics

Enterprise value
4.29B
PEG ratio
0.00
Price / sales
8.06
Price / book
8.57
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
39.30%
Free cash flow
130.45M
Total cash
250.48M
Total debt
29.00M
Return on equity
33.04%
Short % of float
13.04%
50-day average
62.20
200-day average
34.64

Financials — quick view

All financials
CDNA Revenue — quarterly 139.36M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
CDNA Net income — quarterly 19.29M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
CDNA EPS — quarterly 0.37
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

CDNA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 23, 2027Dec 30, 20260.3633———
Oct 29, 2026Sep 30, 20260.25480.70+0.45+174.73%
Jul 30, 2026Jun 30, 20260.23210.37+0.14+59.41%
Apr 28, 2026Mar 31, 20260.110.34+0.23+209.09%
Feb 24, 2026Dec 31, 20250.01990.12+0.10+503.02%
Nov 4, 2025Sep 30, 2025-0.081920.0319+0.11+138.94%

Upgrades / downgrades

CDNA analyst upgrades and downgrades
DateFirmActionFromTo
Oct 30, 2026BTIGmainBuyBuy
Oct 27, 2026BTIGmainBuyBuy
Oct 19, 2026Canaccord GenuitymainBuyBuy
Sep 24, 2026BTIGmainBuyBuy
Sep 2, 2026Canaccord Genuityinit—Buy
Aug 6, 2026BTIGmainBuyBuy

About CareDx, Inc.

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Website
caredx.com

News

Your note

Sign in to keep a note on CDNA — it syncs with the Stock Master app.

Insider holders

CDNA insider holders
InsiderRelationLatest transactionDateShares held
BICKERSTAFF GEORGE W IIIDirectorSaleAug 4, 2026134,061
COHEN FREDERICK E. M.D. PH.D.DirectorStock GiftNov 2, 2026140,060
GOLDBERG MICHAEL DDirectorStock Award(Grant)Oct 1, 2026153,371
HANNA JOHN WALTER JRChief Executive OfficerSaleJul 15, 2026653,448
JAIN ABHISHEKChief Financial OfficerSaleApr 6, 2025337,418
KENNEDY KEITH SChief Operating OfficerStock Award(Grant)Apr 19, 2026221,548

Institution ownership

CDNA institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.16%4,814,709367.51MJun 29, 2026
State Street Corporation4.70%2,468,858188.45MJun 29, 2026
Vanguard Capital Management LLC4.18%2,197,475167.73MJun 29, 2026
Deerfield Management Company, L.P3.80%1,997,618152.48MJun 29, 2026
ARK Investment Management, LLC3.72%1,953,531149.11MJun 29, 2026
Boston Partners3.69%1,937,601147.90MJun 29, 2026

Fund ownership

CDNA fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.96%1,554,868118.68MJun 29, 2026
ARK ETF Trust-ARK Genomic Revolution ETF2.86%1,504,845114.86MSep 29, 2026
BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd.2.61%1,373,550104.84MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.53%1,329,541101.48MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.51%1,321,241100.85MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.12%588,49444.92MJun 29, 2026